Local authorities no longer require routine PMS studies; GSK does not believe the study would add meaningfully to the safety data already available for MMRV.

This study will collect data on the safety of the MMRV vaccine (Priorix-Tetra™) used in routine practice in children aged 12 months to 12 years living in the Philippines.

The participating physicians will enroll only those subjects for whom they would prescribe Priorix-Tetra in the course of their normal clinical practice.

Inclusion Criteria:

• Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.

• Written informed consent obtained from the parent(s)/LAR(s) of the subject.

• Male or female subjects living in the Philippines between, and including, the ages of 12 months and 12 years at the time of the vaccination.

• Female subjects of child bearing potential may be enrolled in the study, if the subject:

  • has agreed to be abstinent or practiced adequate contraception for 30 days prior to vaccination, and
  • has a negative pregnancy test on the day of vaccination, and
  • has agreed to continue adequate contraception during the entire treatment period and for 3 months after completion of the vaccination.

Exclusion Criteria:

• Child in care.
• Any contraindications to vaccination as stated in the Prescribing Information.
• Acute, severe febrile illness at the time of enrollment. The presence of a minor infection, such as a cold, will not exclude the subject from the study.
• Previous receipt of a measles, mumps, rubella and/or varicella-virus containing vaccine less than 3 months prior to study entry.
• Previous enrolment in this trial.
• Subjects with impaired immune function, including primary or secondary immunodeficiencies based on medical history.
• History of hypersensitivity to any component of the vaccine.
• History of hypersensitivity following previous administration of measles, mumps, rubella and/or varicella-virus containing vaccines.
• Receipt of human gamma globulins or a blood transfusion within 3 months prior to study entry.
• Hypersensitivity to latex.
• Pregnant or lactating female.

Children aged 12 months to 12 years living in Philippines will receive Priorix-Tetra as prescribed by the physician.